Year: 2025

G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program

Written by Customer Service on December 9, 2025. Posted in Dividend Reports And Estimates.

Net Income Per Diluted Share of $1.84 and Non-GAAP Net Income Per Diluted Share of $1.90 for the Third Quarter, Both Exceeding Guidance Net Sales of $988.6 Million for the Third Quarter Raises GAAP and Non-GAAP Net Income Per Diluted Share Guidance Maintains Strong Cash and Availability Position Introduces First Ever Quarterly Dividend of $0.10 Per ShareNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-III” or the “Company”) today reported results for the third quarter of fiscal 2026, ended October 31, 2025 and announces approval of a quarterly dividend. Morris Goldfarb, G-III’s Chairman and Chief Executive Officer, said, “We delivered a strong third quarter with gross margins and earnings far exceeding our expectations. This was driven by the strength of our go-forward portfolio, particularly...

Exodus Movement, Inc. November 2025 Treasury Update and Monthly Metrics

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Digital asset holdings facilitate Exodus’ agreement to acquire W3C OMAHA, Neb., Dec. 09, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus’ corporate treasury, as well as updated user and exchange provider processed volume metrics, as of November 30, 2025: Selected Digital Asset Holdings (Unaudited)Bitcoin (BTC): 1,902 BTC as of November 30, 2025, compared to 2,147 BTC as of October 31, 2025.Of the 1,902 BTC held as of November 30, 2025, 1,116 BTC is pledged as collateral under the Company’s credit facility with Galaxy Digital.Ethereum (ETH): 2,802 ETH as of November 30, 2025 compared to 2,784 as of October 31, 2025.Solana (SOL): 31,050 SOL as of November...

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellence Agreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory milestones and a mid-double-digit-gross-profit-share upon launch Clinical development phase of FYB206 nearly completed; primary endpoint data expected in the first quarter of 2026PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) — Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today...

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) remained progression-free for four or more years following treatment with Kisqali® (ribociclib) plus endocrine therapy (ET)1. Results were from a pooled, post-hoc exploratory analysis of first-line patients in the MONALEESA trials and will be presented...

Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle opener

Written by Customer Service on December 9, 2025. Posted in Public Companies.

Heineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls.Heineken® 0.0 x LÕK serve up the world’s first padel racket with a built-in bottle openerHeineken® 0.0 and premium racket brand LÕK announce the first-ever padel racket with a built-in bottle opener and six-pack branded balls The launch adds to Heineken® 0.0’s expanding presence in padel, adding to its new global partnerships with Playtomic and Premier PadelAMSTERDAM, Dec. 09, 2025 (GLOBE NEWSWIRE) — Heineken® 0.0 and LÕK today announce the Special...

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Written by Customer Service on December 9, 2025. Posted in Public Companies.

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today released a year-end Letter from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026. In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science. “We recruited and dosed our first patients in a Phase IIb study. Through a further investment in PsyLabs we secured our psychedelic...

Gencor Releases Fourth Quarter and Fiscal Year 2025 Results

Written by Customer Service on December 9, 2025. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the fourth quarter ended September 30, 2025 of $18.8 million, down 10.0% from $20.9 million net revenue for the quarter ended September 30, 2024. Gross profit as a percentage of net revenue was 24.2% for the quarter ended September 30, 2025, compared to 25.6% for the quarter ended September 30, 2024. The lower gross profit margin in fiscal 2025 was due to reduced manufacturing overhead absorption. Operating loss for the quarter ended September 30, 2025 was ($0.2) million compared to operating income of $1.2 million for the quarter ended September 30, 2024 due to lower gross profit margins and higher selling, general and administrative (“SG&A”) expenses. The Company had net...

SailPoint Announces Fiscal Third Quarter 2026 Results

Written by Customer Service on December 9, 2025. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, today announced financial results for its fiscal third quarter ended October 31, 2025. The company’s earnings release and presentation can be accessed on the quarterly results section of SailPoint’s investor relations website. SailPoint will host a conference call today at 8:30 a.m. Eastern Time to discuss the results and outlook, which is accessible here. About SailPoint At SailPoint (Nasdaq: SAIL), we believe enterprise security must start with identity at the foundation. Today’s enterprise runs on a diverse workforce of not just human but also digital identities—and securing them all is critical. Through the lens of identity, SailPoint empowers organizations to seamlessly manage and secure access to applications...

AutoZone 1st Quarter Total Company Same Store Sales Increase 4.7%; Domestic Same Store Sales Increase 4.8%; 1st Quarter EPS of $31.04

Written by Customer Service on December 9, 2025. Posted in Earnings Releases And Operating Results.

MEMPHIS, Tenn., Dec. 09, 2025 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $4.6 billion for its first quarter (12 weeks) ended November 22, 2025, an increase of 8.2% from the first quarter of fiscal 2025 (12 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows: Constant Currency 12 Weeks 12 Weeks* Domestic 4.8 % 4.8 %International 11.2 % 3.7 %Total Company 5.5 % 4.7 %* Excludes impacts from fluctuations of foreign exchange rates. For the quarter, gross profit, as a percentage of sales, was 51.0%, a decrease of 203 basis points versus the prior year. The decrease in gross margin was driven by a 212 basis point non-cash LIFO impact, partially offset by other net margin improvements....

Descartes Announces TSX Acceptance of Normal Course Issuer Bid

Written by Customer Service on December 9, 2025. Posted in Public Companies.

WATERLOO, Ontario and ATLANTA, Ga., Dec. 09, 2025 (GLOBE NEWSWIRE) — The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) today announced that the Toronto Stock Exchange (the TSX) has accepted Descartes’ notice to launch a Normal Course Issuer Bid (the Bid). Under the Bid, Descartes may repurchase on the open market, at its discretion during the period commencing on December 11, 2025 and ending on the earlier of December 10, 2026 and the completion of purchases under the Bid, up to 8,568,582 common shares, representing approximately 10% of the “public float” (within the meaning of the rules of the TSX), subject to the normal terms and limitations of such bids. Under TSX rules, the average daily trading volume of the common shares on the TSX during the six months ended November 30, 2025 was approximately 204,706...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals